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ABSTRACT
Chronic Kidney Disease (CKD) has been implicated in multiple conditions including
cardiovascular related diseases and Type 2 Diabetes (T2D). Decreased filtration results in
accumulation of urea, electrolytes, and uremic which are implicated in disease progression.
Examination of the progression of CKD effect on vascular regeneration, and T2D development
are necessary. First, examination of CKD progression and buildup of uremic toxin indoxyl
sulfate (IS) was undertaken. In vivo and in vitro analysis implicated CKD and IS accumulation in
impaired vascular regeneration increasing risk of mortality. CKD and the concomitant increase
in IS resulted in impaired regeneration through alteration to vascular smooth muscle (VSMC).
VSMCs exhibited alteration in actin cytoskeletal structure, and decreased motility. This was
driven by loss of focal adhesion protein focal adhesion kinase (FAK). Loss of FAK resulted in
decreased signal transduction for neuronal Wiskott-Aldrich syndrome protein (N-WASP)
necessary for activation of actin nucleation complex Arp2/3. Secondly, examination was
undertaken into T2D progression. High-fat induced T2D resulted in a significant increase in
Neuropilin 1 (Nrp1) expression in vascular endothelial cells. Transmembrane Nrp1 receptor is a
single-pass glycoprotein with well-established roles in vascular events, including tumor
angiogenesis, hypoxia, and growth factor-mediated signal transduction. Increased expression
of Nrp1 led to alteration in insulin signaling. Altered insulin signaling by Nrp1 contributed to
insulin resistance. Thus, our studies demonstrate that CKD induced accumulation of IS impaired

vascular regeneration through loss of VSMC motility and impaired vascular regeneration. Also,
it was determined that T2D induced expression of Nrp1 resulted in altered insulin signaling and
exacerbating insulin resistance.
INDEX WORDS: Indoxyl Sulfate, Chronic Kidney Disease, Focal Adhesion Kinase, Neuropilin
1, Type 2 Diabetes, Insulin
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1

INTRODUCTION

Chronic Kidney disease (CKD) is a condition that is defined as any condition that causes
reduced kidney function over a period and affects roughly 13.6% of adult Americans (NIH).
Currently research is ongoing into uremic toxins that are poorly dialyzable in these patients.
These compounds produce a myriad of effects that range from cellular hypertrophy to apoptosis.
Compounds that have been shown to cause cardiovascular involvements include, p-cresol,
indoxyl sulfate, indole-3-acetic acid, and trimethylamine-N-oxide. Of these toxins indoxyl
sulfate has been shown to be the most potent that has been shown to involve the cardiovascular
system, renal system, and neural system (1).
Indoxyl sulfate (IS) is a potent uremic toxin that in normally functioning kidneys is easily
excreted. However, chronic kidney disease (CKD) prevents renal filtration and directly causes
retention of uremic toxins with multiple pathologic consequences. CKD patients have an above
average mortality due to cardiovascular complications that are a direct result of uremic toxin
accumulation. CKD patients exhibit a multitude of cardiovascular complications including left
ventricular hypertrophy, dilated cardiomyopathy, and atherosclerosis (2). IS is produced from
the degradation of tryptophan by intestinal microbiota. Within this system indole is used as a
potent cellular signal that is used to maintain balance within the intestinal microbiota
environment. This prevents the rise of potentially pathogenic bacteria that can lead to dysbiosis
within the intestines (3). These complications arise due to the prolonged exposure of IS on
various cell types of the cardiovascular system, and renal system.
1.1

Indoxyl Sulfate Generation
IS production is due to a combination of intestinal microbiota degradation of tryptophan,

for the purpose of extracellular and intercellular signaling, and hepatic modifications to
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potentiate excretion. Indole signaling is necessary for biofilm formation by Escherichia coli, and
other bacteria (4). Indole is necessary for bacteria to develop drug resistance, spore formation,
and virulence. Production of indole is carried out by a variety of bacteria that encompass both
Gram-positive and Gram-negative bacteria (5).
IS is produced by metabolism of dietary tryptophan into indole by bacterial derived
tryptophanases. These enzymes cleave indole from the amino portion to provide a food source
for bacterial metabolism. Once indole enters circulation, through the intestinal lumen, it is
transported to the liver. In the liver indole is converted to indoxyl, by the addition of a hydroxyl
group to the three-carbon position on indole. Hydroxylation at the three-carbon position allows
for the addition of a sulfate to the three-carbon position by a liver sulfotransferase (6). After IS
is formed it re-enters circulation and strongly binds to albumin. Albumin then transports IS
through the circulation to the kidney’s to be excreted. Addition of a sulfate group to indole
labels the compound for excretion. In normal patients, the level of circulating IS range around
2mg per liter. This level is variable depending on the study that is reviewed.
When a person is afflicted by chronic and acute kidney disease IS cannot be excreted
properly and begins to accumulate within the patient. IS is poorly dialyzed from CKD patient’s
due to the high binding affinity that it has to serum albumin. The only proper way to remove IS
from circulation is for the patient to receive a kidney transplant so that IS can be properly
excreted (7).
1.1.1

Indoxyl Sulfate Generation

IS transportation is dependent on Organic anion transporters (OATs) specifically OAT1
and OAT3 in renal tubules, endothelial, skeletal muscle, and vascular smooth muscle cells.
OATs play a role in the transport of IS across the renal tubule, however, as OAT3 expression
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decreases in renal tubules leading to a possible mechanism for accumulation of IS. OAT3 has
been theorized to be necessary for the excretion of IS from the kidneys. However, in other cells
outside of renal cells there are shown to be increases in OAT3 expression that plays a major role
in the transport of IS into cells (8).
Once transported into the cell IS will bind with the Aryl Hydrocarbon Receptor (AhR)
and activates certain genes by binding to Aryl Hydrocarbon Receptor Nuclear Translocator
(ARNT) transcription factor which will activate multiple transcription factors that increase
transcription of genes associated with apoptosis, inflammation, and damage responses (9). These
activate genes, and transcription factors are dependent on cell type. AhR activation was
determined through the transcription of genes associated with AhR. These genes include
CYP1A1, CYP1B1, UGT1A1, UGT1A6, IL6, and SAA1. Figure 1 graphically represents the OAT
to AhR pathway involved in pathogenesis. These genes when measured in cell culture, and
tissue samples can act as a marker for AhR induced transcription. It should be stated that IS has
a high affinity and high potency when bound to AhR. Based on current research IS appears to be
one of the few truly potent activators of endogenous AhR (10).
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Figure 1: AhR Activation in IS Exposure
When IS is transported into Endothelial cells through Organic Anion Transporter 3
(OAT3) it will encounter Aryl Hydrocarbon Receptor (AhR) it causes it to disassociate from
Hsp90 proteins. Once IS is bound to AhR it is transported to into the nucleus and binds to ARNT
that acts as a transcription factor that causes expression of CYP1A1, CYP1B1, UGT1A1,
UGT1A6, IL6, and SAA1. This causes the cells to activate inflammatory pathways that effect
cellular viability. IS also results in decreased phosphorylation of AKT, and an increase in HIF1⍺. HIF-1⍺ activation within the kidney endothelium causes a hypoxic effect within the kidney
thus leading to decreased expression of EPO and decreasing endothelial cell proliferation.
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1.2

Cardiovascular Disease Exacerbated by Chronic Kidney Disease
Numerous studies have been undertaken to elucidate the effects CKD has on CVD. In a

multi-year CKD study that examines the prevalence and mortality of a large cohort of patients in
Taiwan was undertaken. They demonstrated an overall 83% increase in mortality in all CKD
patients; further co-morbidity with CVD resulted in a 100% increase in mortality over healthy
individuals. One surprising factor that was observed in this study was the number of participants
who were unaware they had CKD. Age exacerbates the death rate in CKD patients due to
comorbidities such as CVD. The rate at which patients are unaware of their underlying
conditions which prevents proper treatment and mitigation of the condition (11). It has been
determined that younger patients who are aware of their condition and seek medical intervention
experience decreased mortality compared with older individuals (12).
Most studies it should be stated that most of these studies have been done on the adult
population however recent studies have focused on the correlation of CKD and pediatric
mortality. Children who suffer from late-stage CKD exhibit multiple pathologies indicative of
CVD including left ventricular hypertrophy, carotid artery intima-media thickness, carotid
arterial wall stiffness, and coronary artery calcification.

1.2.1

Cardiac Cell Dysfunction

Early research into the effects of uremic toxins effect on cardiovascular disease centered
on cardiac complications. First it was necessary to determine the effect IS has on markers of
cardiac fibrosis. Utilizing IS-exposure in Dahl Salt normotensive versus hypertensive rats
demonstrated there was a significant increase in fibrotic markers, and cell size. These factors
include -smooth muscle actin, transforming growth factor 1 (TGF-1), and type 1 collagen.
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Oxidative marker NADPH oxidase 4 (Nox4) is increased, and inhibition of anti-oxidative
markers Heme Oxygenase 1 (HO-1) and Nuclear like-factor 2 (Nrf2). The increase of the
fibrotic markers leads to heart stiffness and eventual failure. These data demonstrate that IS has
a direct effect on cardiac dysfunction (13).
After it was determined that cardiomyocytes exhibit increased fibrosis, cell size, and
increased oxidative stress it became necessary to delve into the mechanistic pathways involved
in cardiac dysfunction. Firstly, it was again demonstrated that cardiomyocytes exhibit increased
ROS production, decreased cell viability in a dose and time dependent manner, and cell size.
Next, mechanistic analysis was utilized to elucidate the pathway by which cardiomyocyte
dysfunction is potentiated via IS. Uncoupling protein 2 (UCP2) has been shown to be protect
cardiomyocytes by inhibiting ROS production; however, IS-exposure results in UCP2 is
downregulation thus leading to increased levels of ROS. AMP-activated protein kinase (AMPK)
was also examined for its potential role in activating UCP2. As cardiomyocytes are exposed to
IS; phosphorylation of AMPK decreases demonstrating that IS inhibits the activation of AMPK.
Consequently, when cardiomyocytes were exposed to an AMPK activator there was a recovery
in UCP2 expression, and conversely, inhibition of AMPK reduced UCP2 expression. Thus,
demonstrating that AMPK activation or deactivation directly effects UCP2. Further
demonstrating that IS-induced deactivation of AMPK will results in decreased UCP2 and an
increase in ROS production. Activation of AMPK or overexpression of UCP2 was further
utilized to demonstrate that recovery of this pathway inhibits hypertrophic markers and reduces
cell size (14).
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1.2.2

Indoxyl Sulfate Effect on Vascular Endothelial Dysfunctions

IS causes activation of inflammatory cytokines that cause arrest of cellular proliferation.
This damage will lead to weakening of ventricles and weakened arteries that could rupture due to
increased stress due to hypertension. As mentioned above AhR is the intracellular receptor
responsible for binding IS and activating the production of pro-inflammatory cytokines.
Endothelial cells when exposed to IS exhibit dysfunction due to increasing levels of ROS. IS
causes the expression of monocyte chemotactic protein-1 (MCP-1) and decrease in the
production of nitric oxide. This is caused increased production of ROS, and activation of AhR.
ROS production is induced through the activation of Nox4. The increase in MCP-1 causes
increased inflammation of the vascular endothelium (15).
Erythropoietin (EPO) is an erythropoiesis-stimulating cytokine that initiates endothelial
proliferation of vascular endothelial cells through activation of the eNOS pathway. CKD
patients have been shown to exhibit anemia due to reduced expression of erythropoietin.
Research was undertaken to demonstrated IS also prevents the expression of EPO through
suppression of nuclear localization of hypoxia-inducible transcription factor (HIF). Loss of
nuclear localization of HIF results in a desensitization of the kidney oxygen-sensing pathway
preventing the release of EPO, thus possibly effecting other cellular systems (16). The next
question that had to examined was does IS affect EPO pathways and through which mechanism.
Successive research done by Adelibieke et al. demonstrated that IS inhibits EPO signaling
through inhibition of AKT phosphorylation. Decreased AKT phosphorylation was traced back to
erythropoietin receptor (EPOR) inactivation in the presence of EPO. EPOR induced loss of
AKT phosphorylation then directly interfered in EPO activation of eNOS. These aberrations in
the EPO pathway directly led to endothelial dysfunction and apoptosis. Caspases 3 and 7 are
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directly increased after IS stimulation in endothelial cells providing direct evidence of elevated
apoptosis rates. From this it can theorized that aberrations in the EPO pathway may be due to IS
induced resistance to EPO (17).
Paradoxically, there has been research that demonstrates IS can induce angiogenesis
however, contradictory experimentation demonstrated a decrease in neovascularization. Firstly, it
was demonstrated that IS could induce angiogenesis through ROS production and CYP1B1dependent manner. CYP1B1 as previously stated is a target of the AhR response. However,
contradicting research has demonstrated that IS affected the recruitment of endothelial progenitor
cells (EPC) and neovascularization in CKD. IS-exposure resulted in impaired recruitment of
EPCs that was directly linked to reduced neovascularization which potentiates blood flow
disruption. Taking those two contradictory experiments it can be stated that further work must
be done to fully investigate the role IS plays in endothelial dysfunction.

1.2.3

Indoxyl Sulfate Induced Complications in Vascular Smooth Muscle

As vascular smooth muscle is a prominent part of the vascular system it is only
reasonable that this tissue will be affected by IS exposure. Vascular smooth muscle is shown to
undergo increased proliferation due to the activation of the (Pro)renin receptor. This is achieved
through IS stimulating the expression of NF-kB due increased activity by transporter OAT3, and
transcriptional activation by AhR. This effect in conjunction with oxidative stress causes the
increased proliferation of smooth muscles cells. Increased smooth muscle proliferation will
produce thickening of vascular walls and promotes calcification in hypertensive models.
(Pro)renin receptor activation causes increased cell proliferation during IS exposure; it has also
been shown that platelet derived growth factor beta (PDGF-) and ROS are involved in the

9
proliferation and migration of smooth muscles cell (18-19). Activation of p38 MAPK, and
NADPH oxidase in the presence of IS-induced ROS production increased proliferation, and
migration due to the increased sensitivity to PDGF- due to IS exposure (20).
Angiotensin II activation axis is a model of study into the progression of atherosclerosis.
When vascular smooth muscles were exposed to IS, and angiotensin II it was observed that ERK
activation was significantly upregulated, but ERK expression levels did not increase. This
increase in ERK activation leads to increased VSMC migration. It was also determined that
when smooth muscle cells were exposed IS epidermal growth factor receptor (EGFR) had
increased expression. EGFR has previously been reported to be upregulated during angiotensin
II induction (21). Previously stated it has been shown that IS causes the expression of PDGFR
due to ROS production. When ROS inhibitors were employed to determine if EGFR responded
in the same manner as PDGFR it was determined that EGFR levels decreased in antioxidant
treated cells. EGFR phosphorylation was also increased when treated with both angiotensin II
and IS; angiotensin II induction alone showed increased phosphorylation but not at the levels
experienced in the dual treatment. Thus, showing that IS can exacerbate the effects of
angiotensin II on vascular smooth muscle cells (22). IS has a mode of action that increases
apoptosis leading to increased pathogenesis. This is achieved through activation of certain prosenescent proteins increase pathogenesis. Within renal proximal tubular cells NF-kB p65 has
increased expression by IS induction, which causes the activation of genes such as p53, -SMA,
and TGF-1. Through activation of senescence pathways there is a concomitant decrease in cell
division and increased fibrotic gene expression in the proximal tubules. Senescence of the
proximal tubular cells thus exacerbates the renal dysfunction causing further progression of CKD
(23).
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NF-kB activation of senescence has also been reported in the progression of vascular
smooth muscle dysfunction. Oxidative stress is induced by IS exposure leading to upregulation
of senescence markers p53, p21, and prelamin A. Even though it has been shown that vascular
smooth muscles undergo increased proliferation, paradoxically senescence is also upregulated in
VSMC. Senescence marker increase causes the cell to downregulate the expression of FACE1
which is a metalloproteinase responsible from cleaving prelamin A to lamin A. Lamin A is an
integral part of the nuclear membrane that requires FACE1 processing to be functional. Build-up
of prelamin A will then result in DNA damage and mitotic dysfunction that can directly related
to cell death and senescence (24).

1.2.4

Indoxyl Sulfate-induced Skeletal Muscle Atrophy

Skeletal muscle atrophy is a pathologic hallmark of CKD which leads to loss of protein,
and a decrease in muscle mass (Wang et al. 2014)25. One recently elucidated pathway is related
to the release of cytokines and increase in ROS. Skeletal muscle exposure to IS results in release
of inflammatory cytokines such as TNF-, IL-6, and TGF-1, all these cytokines have been
shown to increase in multiple tissues. Following upregulation of inflammatory cytokines there’s
a resultant increase in myokine Myostatin. Myostatin has previously been linked to skeletal
muscle atrophy, but until this study it was not sure by which possible pathway it was interacting
with (26-27). Due to the increase of ROS in skeletal muscle cells caused by IS-exposure;
myostatin expression increased through NF-kB induction in response to inflammatory cytokines.
Previously it had been shown that myostatin will cause increased ROS production through
stimulation of TNF- and NF-kB (28-29). This increased expression of ROS thus in turn causes
increased myostatin leading to increased muscle atrophy. Until this point the control mechanisms
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for myostatin was unknown, but pharmacologically inhibition through anti-inflammatories
prevented muscle atrophy. Atrogin-1 is an E3-ligase linked to skeletal muscle proteolysis has
been directly linked to muscle wasting. When myostatin or TGF-1 are upregulated, there is a
concomitant activation of Atrogin-1. Then the question becomes how these components control
atrogin-1 upregulations. Atrogin-1 expression has been directly linked to upregulation of
Smad2/3 (30). It has previously been shown that TGF-1 and myostatin control expression of
Smad2/3. This directly links expression of myostatin and TGF-1 to IS-induced atrogin-1
skeletal muscle atrophy (Figure 2) (31).

Figure 2: IS Induced Skeletal Muscle Atrophy
When IS encounters OATs on the surface of skeletal muscle cells IS is transported into
the cell and binds to AhR. Once activated AhR is translocated to the nucleus through the action
of ARNT and causes the transcription of inflammatory cytokines such as, IL-6, and TNF-⍺. This
in turn causes increased expression of Myostatin leading to muscle atrophy. Once myostatin is
upregulated there is increased activity of Atrogin-1, an E3-ligase, that causes protein degradation
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leading to muscle wasting. Muscle atrophy is achieved through the upregulation of myostatin
through increased ROS production and activation of NF-kB.

1.3

Type II Diabetes and Chronic Kidney Disease
Type II diabetes (T2D) can be characterized by insulin insensitivity and inhibited glucose

response. Examination of multiple facets of associated with diabetes open alternate pathways of
examination. Vascular systems are made up of multiple cell types that react in various ways to
stimuli. It has been observed that endothelial cells are particularly affected by uremic toxin
exposure. The insulin signaling pathway is a complex signaling pathway necessary for glucose
uptake and utilization. Insulin signaling starts by the interaction insulin with insulin receptor
alpha (IR-) which in turn phosphorylates the insulin receptor beta (IR-). IR- will then
potentiate this signal by activating insulin receptor substrate 1 (IRS-1) which allows for signal
propagation and activation (32). Endothelial cells line the entirety of blood vessels and are the
first line of exposure to toxins and elevate insulin levels.
T2D has been shown to exacerbate multiple disease conditions, including T2D, leading to
increased mortality. In the case of T2D multiple studies have demonstrated a relationship to
CKD and subsequent disease progression (33-34). Patients who suffer from both T2D and CKD
are at increased rates of CVD that directly contributes to mortality. By understanding the disease
progression into T2D will shed light onto how CKD is potentiated and open new treatment
directions.
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1.4

Treatment to Combat Indoxyl Sulfate Accumulation
Currently there are few treatments to reduce production of IS from indole produced by

the intestinal microbiota. One way that indoxyl levels are reduced in CKD patients is through
the treatment with AST-120. AST-120 is an oral sorbent compound that will bind to indole
within the lumen of the intestines which allows for it to be excreted in feces. This method is
used to help reduce the levels of IS and decrease the cardiovascular complications that arise from
the increased levels of IS (35).
Another treatment that has shown so effect in counteracting the effect of IS is treatment
with Vitamin C and N-Acetylcysteine. As stated previously IS acts to increase the level of
antioxidants that cause many of the cellular dysfunctions that are experienced by CKD patients.
Both compounds act as ROS scavengers to reduce the oxidative stress that occurs due to the
increasing levels of IS (36). Another way to control the levels of IS in CKD patients is for them
to ingest very low protein diet to reduce the intake of tryptophan so that indole is produced in
smaller quantities within the bacterial community (37). CVD disease progression could be
blunted in CKD patients by inhibiting IS production. Thus, preventing CKD patients from
increased mortality.
Recently, work has been done to develop a new method of dialysis to remove IS from
CKD patient serum. Until this point there is not a commercially available method to remove IS
from its albumin carrier. In the development of a new dialysis method; poly-cyclodextrans were
chosen for their binding ability to multiple molecules. It was demonstrated that addition of polycyclodextrans to dialysis setups increased removal of IS compared to conventional dialysis. This
new method provides new hope in the future for better dialysis setups to reduce IS
concentrations and reduce cardiovascular complications (38).
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2.1

MATERIAL AND METHODS

Cell culture
VSMCs were purchased from American Type Culture Collection (ATCC) and

maintained in SmGM (Lonza) with 10% FBS. All cells were maintained at 37°C in 5% CO2
and 95% air. All 3T3-L1 fibroblasts and all cancer cell lines including H1792, HepG2, H1299,
and H1650 were purchased from American Type Culture Collection (ATCC) and maintained
in either DMEM F-12 50/50 or RPMI-1640 medium (Lonza) with 10% FBS. HUVECs (Thermo
Scientific, USA) were cultured in EGM-2 basal medium supplemented with EGM-2 BulletKit
(Lonza). HASMCs (Thermo Scientific, USA) were cultured in Medium 231 (Catalog
#M231500; Thermo Fisher, USA) supplemented with smooth muscle cell growth supplement
(Catalog #1101; Sciencell, USA). Adipocyte differentiation studies were carried out by using
DMEM F-12 50/50 added with 3T3-L1 differentiation kit (Catalog #: K579; BioVision, USA).
All cells were maintained at 37°C in 5% CO2 and 95% air.
2.2

Hindlimb Ligation
Mice were fed 0.25% Adenine diet for 1.5 weeks followed by 0.5 weeks recovery before

surgery (21). Hindlimb ligation was performed as previously described (22). Blood flow
restoration was examined at days 0, 1, 3, 7, 14, 21, and 28 days using laser doppler. Mice were
sacrificed at the end of the experiment and tissues were collected for WB and IF examination.
Tissue was either stored in formaline fixative solution or -80C.
2.3

HPLC determination of IS
Sample preparation for plasma was done by mixing 50μl of sample by vortexing in a 1.5ml

eppendorf tube with 1/10 volume of ice-cold 2.4 mol/L perchloric acid. The cloudy suspension
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was chilled on ice for 15’ and then centrifuged at 8,000g for 3 minutes. The clear protein-free
supernatant was analyzed directly. IS content was estimated along with standards ranging from
0.250-25μM IS (Sigma, I3875), using a C18 column (Symmetry C18 Column, 100Å, 5 µm, 4.6
mm X 250 mm; Waters, USA). The mobile phase was ACN/H2O: 66/34 and the injected sample
volume was 20 l. The flow rate was 1 ml/min at 38 C. The column effluent was monitored at
278nm by a UV detector.
2.4

Cell Attachment and Size Assay
ECM Laminin (20ug/mL), Fibronectin (10ug/mL), and liquid gelatin were diluted in PBS

and incubated on plates for 1 hour. Plates were blocked with 5% BSA for 1 hour to prevent
nonspecific binding. Cells were plated on ECM for 6 hours in 2% FBS media then fixed with 4%
paraformaldehyde. Stained with Phalloidin (1:1000) for 20minutes and mounted with DAPi gold
mounting media. Size was determined as previously described.
2.5

siRNA Transfection
VSMCs were routinely passaged 24 hours before transfection and transfected at

approximately 70% confluency. Cells were transfected with either siRNA for FAK, Paxillin, or NWASP (Santa Cruz Biotechnology) for 6 hours in Optimem (Gibco) using the RNAImax
(Invitrogen) then incubated for 24 hours in 2% FBS media before incubation under normoxic or
hypoxic conditions (1% O2; 12hrs) or further manipulation. Lung cancer cell lines were routinely
passaged 24 hours before transfection and transfected at approximately 70% confluency. Cells
were transfected overnight in 1% FBS media using the RNA IMAX protocol (Invitrogen) before
incubation under hypoxic conditions or further manipulation. Stable Nrp1-deficient cell lines were
achieved using lentiviral shRNAs under puromycin selection (Santa Cruz Biotechnology).
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2.6

Reagents and Cell Treatments
To inhibit the lysosomal activity, Bafilomycin A1 (BafA; 8hrs), Chloroquine (CQ; 8

hours), and to inhibit proteasome degradation Mg132 (8hrs) (Invitrogen, USA) was used. Control
cells were treated with vehicle only (PBS). IS stimulation experiments were done with various
insulin concentrations (nM) for 2 days in 2% serum media. To inhibit the lysosomal activity,
Chloroquine (CQ; 3 hours) (Invitrogen, USA) was used. Control cells were treated with vehicle
only (PBS). Insulin stimulation experiments were done with various insulin concentrations (nM)
at varying time duration (5 to 120 minutes) in serum-starved cells.
2.7

Western Blotting and Immunoprecipitation
As previously described, Western blots were done, and blots were probed with specific

antibodies (23). Primary antibodies used as follows: β-actin and GAPDH anti-mouse monoclonal
antibody (Santa Cruz Biotechnology); anti-rabbit polyclonal FAK, FAK (Y397), Paxillin, Paxillin
(Y118), Hif1, Arp2, and Arp3(Cell Signaling); anti-rabbit polyclonal N-WASP (Sigma). After
background subtraction from the calculated area, band intensities were measured and quantified
by densitometry (GS-700 Imaging Densitometer; Bio-Rad). Quantification of Western blot was
based on the ratio of the target protein to GAPDH or β-actin housekeeping protein.
As previously described, Western blots were done, and blots were probed with specific
antibodies (23). Primary antibodies used as follows: β-actin and GAPDH anti-mouse monoclonal
antibody (Santa Cruz Biotechnology); anti-rabbit polyclonal RAB5, RAB7, RAB11, pAkt
(Ser473), tAkt, pIRS1 (Ser612), tIRS1, PPARγ and C/EBPα (Cell Signaling); anti-rabbit
polyclonal Nrp1 and Lamp2 (Abcam, USA). After background subtraction from the calculated
area, band intensities were measured and quantified by densitometry (GS-700 Imaging
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Densitometer; Bio-Rad). Quantification of Western blot was based on the ratio of the target protein
to GAPDH or β-actin housekeeping protein.
2.8

Light and Confocal Microscopy
Cells were plated on glass coverslips and fixed in 4% paraformaldehyde. Cells were

permeabilized with either 0.1% Triton X-100 and blocked with 0.1% BSA before antibody
addition. Indirect immunofluorescence experiments were performed using the following primary
antibodies: anti-rabbit FAK (1:200; Cell Signal), anti-mouse N-WASP (1:50; Santa Cruz), antimouse Paxillin (1:50; Santa Cruz), anti-rabbit N-WASP (1:50; Sigma), anti-mouse Arp2 (1:50;
Santa Cruz). Secondary antibodies consisted of Alexa Fluor 488, 555, and 647 (donkey anti-goat,
-rabbit, or -mouse, respectively) used at 1:400 dilution.
Cells were plated on glass coverslips and fixed in 4% paraformaldehyde. Cells were
permeabilized with either 0.1% Triton X-100 or 0.2% saponin and blocked with 0.1% BSA before
antibody addition. Indirect immunofluorescence experiments were performed using the following
primary antibodies: anti-goat Nrp1 (1:100; Santa Cruz), anti-rabbit Nrp1 (1:100; Santa Cruz), antirabbit RAB7 and PPARγ (1:100; Cell Signaling), anti-rabbit Lamp2 (1:750; Abcam). Secondary
antibodies consisted of Alexa Fluor 488, 555, and 647 (donkey anti-goat, -rabbit, or -mouse,
respectively) used at 1:400 dilution.
2.9

IHC
Tissues were fixed in 10% ice-cold formalin overnight, then embedded in paraffin. Briefly,

slides were deparaffinized and dehydrated for 30 minutes at room temperature. Sections were
incubated for 30 minutes in diluted normal blocking serum, and primary antibodies were added to
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slides after excess serum had been removed. Respective antibodies against vWF and -SMA
(Santa Cruz Biotechnology) were diluted according to the manufacturer’s instructions.
Tissues were fixed in 10% ice-cold formalin overnight, then embedded in paraffin. Briefly,
slides were deparaffinized and dehydrated for 30 minutes at room temperature. Sections were
incubated for 30 minutes in diluted normal blocking serum, and primary antibodies were added to
slides after excess serum had been removed. Respective antibodies against Nrp1 and Rab7
(Lifespan Biosciences) were diluted according to the manufacturer’s instructions.
2.10 Nrp1 Plasmid Transfection
Nrp1 plasmid was a gift from Christiana Ruhrberg (University College London, UK), and
was transfected in H1299 cells using optiMEM medium and Lipofectamine 2000 transfection kit
(Thermo Fisher, USA).
2.11 Quantitative RT-PCR
Oligos used to quantify as follows: Nrp1 (forward, 5′-GTTCATCCACCGCATCGAC-3′;
reverse,

5′-CACATCCACCAGCTGGATG-3;

277bp′),

Nrp1 (forward,

5′-

AAATGCGAATGGCTGATTCAG-3′; reverse, 5′-CTCCATCGAAGACTTCCACGTAGT-3′;
121bp),

and 18s (forward,

5′-GTCTGTGATGCCCTTAGATG-3′;

reverse,

5′-

AGCTTATGACCCGCACTTAC-3′). Real time quantification was performed by SYBR Green
(Bio-Rad, USA) with the C1000 thermal cycler, CFX96 detection system (Bio-Rad, USA).
Relative gene expression was normalized to 18s and compared using the ΔΔCt method.
2.12 FACS Assay
Insulin internalization into the different cell types was measured using FITC-labeled
insulin (Ins. FITC, Sigma-Aldrich, USA). A monolayer of serum-starved siNrp/si-Scr or
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LacZ/Nrp1-transfected cells were treated with insulin (50nM) for 15 min. The excess insulin was
removed and washed with cold PBS. Fresh serum-free RPMI medium was added to the cells on
ice. Cells were placed back at 37 °C for 10 min. Subsequently Ins.FITC (100nM) in PBS was
added and incubated for 30 min. The reactions were stopped by the removal of Ins.FITC and cold
PBS washes (2×). Cells were fixed in 1% paraformaldehyde, and FITC staining was detected by
flow cytometry (BDLSRFortessa), and data was analyzed using FlowJo software.
2.13 Glucose and Insulin Tolerance Tests
Wild type, Nrp1endo-/- mice and littermates (Nrp1endo+/+) mice were fed with either chow or
high fat diet. Glucose and insulin tolerance tests were performed. Briefly, for the glucose tolerance
test (GTT), the mice were fasted for 16 h. After determining fasted blood glucose levels, each
animal received an intraperitoneal glucose injection of 1 g/kg body weight. Blood glucose levels
were determined at 0, 15, 30, 60, and 120 min. For insulin tolerance tests (ITTs) 4 h fasted mice
received an intraperitoneal injection of 1.5 units/kg body weight of insulin. Blood glucose levels
were measured at 0, 15, 30, 60, and 120 min.
2.14 Statistics
Data are expressed as mean ± SEM or mean ± SD as indicated in the figure legends.
Statistical comparisons were performed using unpaired 2-tailed Student’s t-test or 1-way ANOVA
with Bonferroni multiple-comparison test. A P value less than 0.05 was considered significant.
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INHIBITION OF FAK-ACTIN PATHWAY BY INDOXYL SULFATE SUPPRESSES
ARTERIOGENESIS IN A MOUSE MODEL OF CHRONIC KIDNEY DISEASE

3.1

Abstract
Chronic Kidney Disease (CKD) and the concomitant accumulation of uremic toxins has

been implicated in impaired vascular regeneration and arteriogenesis. The objective of this study
is to examine the role uremic toxin indoxyl sulfate (IS) has on arteriogenesis, vascular
regeneration, and the underlying molecular mechanisms. C57BL6/J mice were fed 0.25%
adenine diet for 1.5 weeks to induce CKD. CKD mice exhibited increased serum levels of
uremic toxin IS, nitrogen, and creatine. Mice underwent hindlimb ligation and CKD mice
exhibited decreased blood flow restoration (44.7% relative blood flow) compared to control
(82.6% relative blood flow) and presented with decreased arteriole formation as evidenced by
reduced VSMC content (decreased -SMA) in vessels of ligated limb. Wound healing and
transwell migrations assays demonstrated IS-exposed VSMCs had significantly reduced motility.
IS-exposure also resulted in disorganized actin cytoskeleton, alterations in actin structure,
attachment, and cell size in VSMCs. Focal adhesions, actin attachment points, were decreased
due to IS-exposure. Specifically, focal adhesion kinase (FAK), a vital component of cell
attachment and attachment, was significantly decreased due to CKD progression and ISexposure. Loss of FAK directly decreased motility and impacted N-WASP expression necessary
for activation of actin polymerization complex Arp2/3. Arp2/3 complex was further affected by
IS-exposure which resulted in decreased expression. Loss of Arp2/3 would thus inhibit motility
through the loss of actin polymerization. Thus, our studies demonstrate that CKD accumulation
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of uremic toxin IS inhibits VSMC motility and impairs vascular regeneration and arteriogenesis
through inhibition of FAK-actin pathway.

3.2

INTRODUCTION
Chronic Kidney Disease (CKD) a serious medical condition that causes not only medical

burden but socioeconomic pressures that are only exacerbated by the ever-increasing disease
prevalence. Figures from 1998 demonstrated, approximately 20 in every 1000 individuals over
the age of 60 were affected by CKD, however by 2012 that figure had more than doubled to 50 in
every 1000 individuals in the United States (1-3).
CKD patients present with decreased filtration of the blood, accumulation of uremic toxins,
and other solutes normally excreted by healthy kidneys. Uremic toxins have been implicated in
the progression of multiple diseases or the exacerbation of already existing conditions. These
compounds are derived from amino acid degradation by gut microbiota. Currently, the most potent
uremic toxin elucidated is that of IS. IS is generated by the degradation of tryptophan by E. coli.
Specifically, E. coli will cleave the function and amino groups and utilize each component. Gut
microbiota will utilize the functional group, indole, as an intracellular signaling molecule (4).
Once indole is released by the microbiota it is cross the intestinal lumen and enters the circulation.
Normally, excess indole will be transported to the liver and undergo sulfonated conversion into
IS. Upon conversion IS will be released into the circulation and quickly binds albumin for
transport to the kidneys for excretion. However, CKD impairs kidney filtration resulting in the
accumulation of IS. As the levels rise cardiovascular complications increase ultimately leading to
mortality (5-6).
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Cardiovascular disease (CVD) is one of the main routes of mortality in CKD patients
especially those in late stage of disease progression. CVD progression has been tied to the
accumulation of said uremic toxins. Uremic toxin accumulation has been shown to cause or
exacerbate dilated cardiomyopathy, coronary artery disease, atherosclerosis, and peripheral artery
disease (PAD). Studies have demonstrated CKD patients are susceptible to PAD which leads to
ischemia, extremity ulcerations, and ultimately infections (38&39). Examination of CKD patients
has demonstrated ~25.2% of patients also suffer from PAD which impairs blood flow and wound
healing. PAD results in narrowed blood vessels leading to impaired collateral formation necessary
for blood flow restoration. CKD patients are known to suffer from leakage at canulation sites which
interferes with hemodialysis preventing proper blood filtration (43). Also, CKD patients are at
increased risk of adverse outcomes from AAA repair and lower extremity amputations. They are
more likely to have failed surgical repairs and or impaired blood flow that will prevent repair and
increase mortality. These reports demonstrate that vascular structure is disrupted, and these
disruptions will directly contribute to impaired vascular regeneration and arteriogenesis (7-9).
Vascular regeneration and arteriogenesis rely on a complex signaling pathway necessary
to activate with expansion of new vessels necessary to alleviate hallmarks, including ischemia,
necrosis, and infections, of impaired blood flow (10&11). Vasculature regeneration first relies on
the activation of endothelial cells to construct new capillaries to begin blood flow blood flow
restoration. These capillaries are essential for nutrients and oxygen to reach the damaged tissue.
However, these capillaries are incapable of high-capacity blood flow limiting the amount of
nutrients and oxygen reaching said wounds. Capillaries experiencing elevated levels of endothelial
shear stress, radial wall stress, and high blood pressure must undergo arteriogenesis to allow for
blood vessel expansion. Arteriogenesis allows for blood vessel expansion through the recruitment
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vascular smooth muscle cells (VSMCs) that will provide support necessary for larger quantities of
blood to pass (45). Disruption of arteriogenesis will prevent blood flow to damaged tissues, and
consequently potentiating. Arteriogenesis not only requires the presence of VSMCs but relies
upon the cellular attachment, cytoskeletal, and migration pathways to be unaffected. Currently,
though elucidation of the molecular underpinnings potentiating these adverse vascular outcomes
has not been investigated as it relates to arteriogenesis and vascular regeneration in CKD patients.
Attachment and migration are controlled by multiple different pathways that include focal
adhesion attachment, and coordination of the cytoskeleton (12-15). Focal adhesions are complexes
responsible for potentiating extracellular stimuli and convey that signal intracellularly. These
complexes are dynamic and designed to respond to multiple stimuli. Responsiveness to these
signals requires the coordination of canonical focal adhesion proteins including Focal Adhesion
Kinase (FAK), Paxillin, Src, p130cas, actopaxillin, vinculin, talin, and many more. Alterations to
these complexes would lead to ineffective response to stimulation of the focal adhesions and
defective vascular repair (16-20). Elucidation of the role uremic toxin IS has on vascular
regeneration and arteriogenesis, and the molecular interplay between the actin cytoskeleton,
regulators of actin structure, and focal adhesions will provide vital insights into disease progression
in CKD patients.
Buildup of uremic toxin IS resulted in alterations to the actin cytoskeleton and formation,
focal adhesions, and motility that impairs vascular regeneration and arteriogenesis mechanisms.

3.3

Results
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3.3.1

Adenine Diet Model of CKD

Firstly, it was necessary to examine the effect CKD has on vascular regeneration and
arteriogenesis. We utilized a CKD mouse model fed 0.25% adenine diet for 1.5 weeks, and then
induced a vascular injury through hindlimb femoral artery ligation (21). Laser doppler analysis of
CKD mice exhibited impaired blood flow restoration (44.7% restoration) compared to controls
(82.6% restoration) after 28 days of recovery in the ligated hindlimb (Figure 3A&B) (22).
Defective vascular regeneration can lead to limb atrophy, increased chances of infection, and
further complications ultimately resulting in mortality. Also, CKD mice presented with elevated
levels of IS, Serum Nitrogen, and Creatine which demonstrate that kidney function is impaired
(Figure 3C-E). Cardiovascular function was examined due to previously reported complications
associated with CKD. Adenine diet induced CKD resulted in cardiovascular complications marked
by increased pulse wave velocity (PWV), and decreased fraction shortening (FS) and ejection
fraction (EF), but no change to strain (Figure 8A-D).
Finally, once it was determined that CKD impaired vascular regeneration the next step was
to examine arteriogenesis of the damaged limb. Importantly, vasculature within tissues can be
classified as capillaries, composed of endothelial cells, or complex vessels, composed of
endothelial cells and VSMCs. Complex vessels, formed through the process of arteriogenesis, are
necessary to carry higher volumes of blood compared to capillaries. Impaired arteriogenesis
contributes to decreased recovery and blood flow capacity. Examination of damaged musculature
in the ligated muscle occurred via immunofluorescent staining for vWF (endothelial cells) and SMA (VSMCs) (23). CKD mice muscles exhibited decreased arteriogenesis as demonstrated by
lack of -SMA in vessels while vWF was present (Figure 3F). Vessels lacking VSMCs were
inadequate to compensate and repair the damage resulting from hindlimb ligation. Our data
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demonstrated that arteriogenesis was impaired due to CKD progression and buildup of uremic
toxins.
The role that tryptophan plays in the progression in CKD progression is well understood
due to the role it plays in uremic toxin formation. Tryptophan deficient diet was utilized to
understand the role in wound healing progression. It was determined that tryptophan deficient diet
resulted in loss of weight and inability to recover from CKD induction (Data not shown).
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Figure 3: Hindlimb Ligation of CKD Mouse Model
A. Heat Map for blood flow restoration after 28 days post-surgery. B. Relative percentage
of blood flow restoration after hindlimb ligation. Adenine diet (AD) mice exhibited
approximately 44.7% blood flow restoration compared to Chow Diet (CD) Mice 82.6%
restoration of blood flow (ND, n=9; AD, n=8). C. To be completed. D. serum Nitrogen levels are
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significantly elevated in Adenine Diet mice. E. To be completed. F. Ligated muscle was stained
for capillaries vWF (Red, endothelial cells), ⍺-SMA (Green, VSMCs) *p<0.05, **p<0.005
3.3.2

Vascular Smooth Muscle Cell Motility

Uremic toxins, specifically IS, which accumulate during CKD progression, are known to
has adverse effects on vascular cells that contribute to cardiovascular disease (44). Firstly, VSMCs
underwent IS-exposure for 2 days and we utilized a wound healing assay to determine the effect
on migratory ability. Examination the migratory efficiency of IS-exposed VSMCs demonstrated
approximately 20% wound closure after 12hrs compared to approximately 35% wound closure in
control samples (Figure 4A&B). Next, a transwell migration assay was employed further examine
IS-exposed VSMC migratory ability. IS-exposed VSMCs were applied to the transwell and after
6hrs migration there was a marked reduction in migratory ability compared to the control.
Migration activator PDGF- was utilized to determine if the phenotype would be reversed upon
stimulation (24). PDGF- only partially rescued IS-exposed VSMC motility, lending evidence
that IS-exposure (Figure 4C&D). It became necessary to examine whether other known activators
could reverse the observed phenotype. Finally, we utilized migration activators FGF, VEGF, and
ANGII were utilized and found to be incapable of reversing IS impaired motility (Figure 4E). This
data demonstrated that IS impaired motility can be ameliorated but not completely reversed. To
ensure that our observations are related to decreased migration and not cell death cell viability was
examined. Cell viability decreases significantly until 4 days after exposure to IS but has minimal
effect after 2 days of exposure (Figure 9A-D). IS-exposure does induce inflammation in VSMCs
due to expression of IL-6 which is consistent with previous reports (25). Our data now lends
compelling evidence that IS-exposure directly inhibits motility.
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Figure 4: Indoxyl Sulfate Effect on VSMC Wound Healing and Migration
A&B. VSMCs exposed to IS had decreased wound healing capacity and results in wound closure
of approximately 20% compared to approximately 40% closure after 12hrs. (1mm scale) C.
Transwell migration assay was utilized for VSMCs exposed to IS for 24hrs. There was a
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signification decrease in VSMC migration. PDGF (10ng/mL) was utilized as a positive control.
PDGF stimulation did stimulate migration however IS-treated cells had less migration than
untreated cells. (1mm scale) D. 48hrs of IS exposure was utilized. Transwell migration yielded
similar results to the 24hrs exposure. Migration was inhibited. (1mm scale) E. Various other
migration stimulators were utilized PDGF, FGF (1ng/mL), VEGF (10ng/mL), and Angiotensis II
(ANGII, 5µM), ***p<0.0005, ****p<0.0001

3.3.3

Indoxyl Sulfate Alters Actin Cytoskeleton and Attachment

Once it was understood that IS-exposure impairs VSMC motility the next question that
needed to be asked was how the actin cytoskeleton is affected. The actin cytoskeleton is directly
involved in motility and due to the impaired motility, it this logically appears to be the next step
of examination (12&13). First, we utilized IS-exposed VSMCS to examine effects on actin
structure and arrangement. IS-exposure induced actin cytoskeletal disorganization as evidenced
through actin staining (Figure 5A). Alteration to the actin cytoskeleton would interfere with normal
cellular functions. Elucidation of the disruptions to the actin cytoskeletons necessitated
examination of actin polymerization in IS-exposure conditions. Within all cells actin exists in two
states either Filamentous-actin (F-actin) or Globular-actin (G-actin). Isolation and examination of
actin states demonstrated IS inhibited polymerization which will decrease the number of actin
fibers (Figure 5B). Further confirmation was sought through IF staining of F- and G-actin. Actin
staining further reinforced the observation that IS-exposure inhibited actin polymerization and
decreased levels of F-actin (Figure 5C). Lending further evidence that IS-exposure alters the
VSMC actin cytoskeleton Inhibition of actin polymerization will result in alterations to
morphology and directly drive the loss of motility previously observed.
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Understanding that IS-induces alterations to the actin cytoskeleton it was necessary to
examine the effect this had on VSMC morphology. Extracellular matrix (ECM) components are
utilized by all cell types to attach and interact with the cellular environment. VSMCs when healthy
are known to prefer binding to Laminin however, in disease conditions ECM affinity has been
shown to be altered. To this end we employed standard ECM or Laminin coated plates to examine
cell attachment, size, and substrate affinity. IS-exposure significantly reduced cell size by as much
as 50% on laminin or standard ECM plates (Figure 5D&E) (26). Alterations to the actin
cytoskeleton led to smaller cells due to lack of structural support to maintain larger cell sizes.
Further analysis of VSMC ECM affinity was undertaken utilizing collagen and fibronectin coated
slides. We found that VSMCs have an increased affinity for collagen and cell size (Supplementary
Figure 3A-C). VSMCs exposed to IS also experienced a change the integrin profile that affected
attachment and response to the extracellular environment (Figure 10D&E). Finally, to examine
focal adhesions, which are attachment points for actin fibers, we utilized IF staining for FAK and
Paxillin (Figure 5F) (27). Focal adhesions are decreased after IS exposure leading to decreased
actin attachment, and size. Taken together this data demonstrated that IS-exposure directly
interferes in the actin cytoskeleton structure, directly leading to alterations of cell size and
attachment ability.
Further analysis demonstrated that VSMCs plated on Fibronectin and Gelatin exhibited
altered cell size (Figure 10A&B).

These alterations resulted changed interaction with the

extracellular environment as evidenced by the alteration in focal adhesions numbers (Figure 10C).
Examination of integrins necessary for attachment to the extracellular matrix was undertaken. It
is demonstrated that there decreases in multiple alpha and beta integrins due to IS-exposure (Figure
10D&E). Finally, we examined the activity of MMPs necessary for ECM degradation was
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undertaken. IS-exposure results in decreased activation of MMP2 as IS levels increase (Figure
11A). It was also demonstrated that ECM component collagen experienced an increased
expression as well. These data lend further evidence that IS-exposure alters VSMC ECM
interaction.
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Figure 5: Indoxyl Sulfate Effect on Actin Cytoskeleton, Cell Size, and Attachment
A. Prolonged exposure to IS results in disorganization of the VSMC actin cytoskeleton.
B. IS also results in decrease actin polymerization thus inhibiting actin fiber formation. C. IF
staining of VSMCs for F- (Red) and G-Actin (Green). IS exposed cells have decreased F-Actin

38
and increased G-actin pool. D. VSMCs were plated on Standard Coating or Laminin (20µg/mL)
coated plates. E. Percentage of cell area with or without IS exposure. F. Focal adhesion in
response to IS exposure. Focal adhesions decrease on Standard Coating, and Laminin coated
plates. **p<0.005, ***p<0.0005
3.3.4

Focal Adhesion Loss Due to Indoxyl Sulfate

Understanding how IS-exposure affected cellular structure and attachment it was necessary
to examine vital attachment known as focal adhesions. Focal adhesions are necessary for
attachment and signal transduction from the extracellular environment. Firstly, we examined how
IS affect the expression of canonical focal adhesion proteins Focal Adhesion Kinase (FAK) and
Paxillin. Dose dependent IS-exposure resulted in significant decrease in the expression of FAK
and Paxillin, and the activation of FAK at Tyr397 (Figure 6A-C) (28). Microscopy demonstrated
that FAK and Paxillin were depleted at the leading edge of VSMCs and throughout the cell (Figure
6D&E). Without these points at the leading edge there will be reduced actin polymerization and
impaired forward motility. FAK and Paxillin are vital components of focal adhesions however
they are not the only proteins present thus leading to question if IS-induced loss if confined to
these proteins. Another two canonical focal adhesion proteins Src and p130cas were examined for
activation and expression after IS-exposure. Analysis determined there was no alteration to
activation or expression of these proteins due to IS-exposure (Figure 6F). In vivo analysis of the
effect CKD has on FAK and Paxillin was necessary. Aortas were isolated from CKD mice,
perivascular adipose tissue and endothelial cells were removed, and were examined via western
blot. Analysis of aortic samples recapitulated the in vitro samples demonstrating a significant loss
of FAK and Paxillin in CKD conditions (Figure 6G). Ligated muscle was examined, and it was
found that vessels lacked FAK expression after CKD induction (Figure 6H)
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Following observations that IS-exposed VSMCs exhibit decreased motility and loss of
focal adhesion proteins it was necessary to elucidate if the loss of focal adhesions directly
contributed to lost motility. FAK or Paxillin were silenced in VSMCs, and the effect on migration
was examined via transwell migration assay. Silencing of FAK resulted in significantly decreased
VSMC motility however, loss of Paxillin had no effect on VSMC motility (Figure 6I). Taken
together these data demonstrate loss of focal adhesion proteins specifically FAK impair vascular
motility and play a role in alterations to the actin cytoskeleton.
We must also consider the microenvironment that is produced during vascular damage and
that is hypoxia. To determine if the microenvironment caused by vascular damage would alter the
mechanism being proposed we utilized hypoxic conditions. Analysis of VSMCs demonstrated that
hypoxia did not alter the expression profile of FAK and Paxillin with or without IS exposure
(Figure 12A). Finally, we also examined the mechanism by which IS induced the loss of FAK and
Paxillin. Utilizing inhibitors for proteasome, early- and late-stage lysosome degradation. We
found that IS induced FAK and Paxillin degradation through the proteasome degradation system
(Figure 12B).
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A. FAK and Paxillin decrease as IS concentration increases. Also results in loss of
phosphorylation. B. FAK relative expression after IS-exposure. C. Phosphorylation of FAK at
Y397 was decreased after IS-exposure D. Focal Adhesion made of FAK and Paxillin are
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decreased after IS-exposure at the leading edge. E. Confocal microscopy further demonstrates
the loss of focal adhesions. F. Related focal adhesion protein p130Cas and Src are not affected
by IS exposure. G. Mice aortas were examined after Adenine diet. FAK and Paxillin is decreased
mimicking in vitro VSMC profile (n=3). H. Ligated muscle from adenine diet fed mice
demonstrated lower expression of FAK in vessels I. Silencing of either FAK, Paxillin, or both
was examined via transwell migration. Silencing FAK had a marked decrease in migration
however, this was not the case with Paxillin silencing. (R.E.- Relative Expression) *p<0.05,
**p<0.005

After understanding that Focal adhesions were involved in the loss of cell motility after ISexposure we needed to understand how loss of FAK and alterations to the cytoskeleton are
propagated. We examined what could be a downstream effector for FAK, Neuronal WiskottAldrich Syndrome Protein (N-WASP) which has been implicated in actin polymerization (28&30).
Examination of N-WASP phosphorylation (S484/485) and total expression after IS-exposure. In
vitro and in vivo samples we determined that IS exposure decreased N-WASP expression as well
as cause the loss of the phosphorylation state (Figure 7A&C). We also utilized staining for FAK
and N-WASP to demonstrate the result of IS exposure. VSMCs exhibited reduced expression of
N-WASP as well as alterations to cellular localization (Figure 7B). Further demonstrating that ISexposure has a direct effect on the ability of VSMCs to construct and utilize the actin cytoskeleton.
To ensure that loss of N-WASP was involved in decreased motility a transwell assay was again
utilized. Silencing of N-WASP severely inhibited migration in the same fashion as loss of FAK
(Figure 7D). Demonstrating that the FAK-N-WASP pathway is directly involved in VSMC

42
migration. Now that we understand that IS affects a particular actin polymerization pathway the
next step is to examine the Arp2/3 complex responsible for actin polymerization.
Expression of Arp2 and Arp3 was directly downregulated after IS exposure in both in vitro
and in vivo models. Once it was determined that another link in the chain involved in actin
nucleation was disrupted, we finally examined the Arp2/3 complex that has been directly tied to
actin nucleation in cells (31&32). It was observed after IS exposure there was a decrease in the
expression of Arp 2 and 3 in vitro and in vivo (Figure 7C, E&F; Figure 13A). This ties directly
into the previous observations of decreased polymerization after IS exposure. Loss of these vital
components of the Arp2/3 complex results in decreased actin nucleation. Taken together it has
been demonstrated that aberrations to actin polymerization are responsible for lost motility.
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actin polymerization. H. Arp2 and Arp3 decreased expression in adenine diet mice. (n=3) I. NWASP and Arp2 colocalization also decreases after IS exposure. **p<0.005

45
3.4

Supplementary Figures

A.

B.

40

8
6
4

30
20
10

2

0

0
d

et
d

i

n

al
rm

n

e

N

de

N

o

i

et

i

A

C.

or

m

al

di

et

A

de

ni

ne

di

et

D.
n .s .

*

0 .3

80

S t r a in

60
E F (% )

*

50

*
F S (% )

P W V ( m m /m s )

10

40

0 .2

0 .1

20

0 .0

ni
de
A

N

or

m

ne

al

di

di

et

et

0

N

or

m

al

di

et

A

de

n

e
in

di

et

Figure 8: Cardiovascular Complications

Supplementary Figure 1: Cardovascular Complecations A. Pulse Wave Velocity (PWV)
was increased due to CKD. B. Fraction Shortening (FS) was elevated in CKD conditions. C.
A. PulseEjection
Wave Velocity
(PWV)
increased
dueconditions.
to CKD. D.
B. Vascular
Fractionstrain
Shortening
Fraction (EF)
was was
decreased
in CKD
was not (FS)
significantly affected by CKD conditions.

was elevated in CKD conditions. C. Ejection Fraction (EF) was decreased in CKD conditions. D.
Vascular strain was not significantly affected by CKD conditions.
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Figure 10: Further Analysis of VSMC Attachment
A. Fibronectin (10ng/mL) and Gelatin (Cellbiologic). Cell size decreased on Fibronectin
after IS exposure and increased on Gelatin. B. Graph of cell size for fibronectin and gelatin. C.
Focal adhesions change on Fibronectin and Gelatin. D&E. Integrins profile for both alpha and
beta subunitss shifted in VSMCs after IS exposure. **p<0.01, ***p<0.005
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Figure 12: Hypoxic Effect on VSMC FAK
A. Examination of the effect of 12hrs Hypoxia on VSMCs exposed to IS. B. Inhibition of
protein degradation after IS exposure.
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4

NEUROPILIN-1 (NRP1) PROTEIN IS A MODULATOR OF INSULIN
SIGNALING FUNCTIONS

4.1

Abstract
Transmembrane neuropilin-1 (Nrp1) receptor is a single-pass glycoprotein with well-

established roles in vascular events, including tumor angiogenesis, hypoxia, and growth factormediated signal transduction. Here we propose a previously unidentified role of the Nrp1 protein
on insulin signaling functions. Our data showed that in obese conditions, high fat diet or insulin
stimulation promoted the expression of Nrp1 in adipose and liver tissues, as well as vascular and
cancer cells. Consequently, abundant Nrp1 availability resulted in increased co-localization with
insulin substrates, thereby modulating the insulin signaling pathway. Interestingly, improved
vascular cell functions were observed under Nrp1-depleted and insulin-challenged conditions.
Nrp1-depletion results in stronger and faster activation of the insulin signaling cascade. For the
first time, these observations uncover novel association and subsequent modulation of insulin
signaling substrates by Nrp1. Potential implications of these findings with respect to cancer risk
and links to metabolic perturbations, such as obesity and insulin resistance, are hereby reported.

4.2

Introduction
Type II Diabetes (T2D) a metabolic condition that is characterized by high blood

glucose levels, insulin insensitivity, and/or decreased insulin levels. Risk factors for T2D can
include family genetic history, age, and/or obesity or a combination of multiple factors. Obesity
results in adipose tissue inflammation and a concomitant increase in serum insulin levels and
insulin insensitivity. Recent evidence has demonstrated that T2D patients are at increased risk

57
of cancer development. As insulin insensitivity progresses and insulin signaling is altered
cancer progression is exacerbated leading to adverse outcomes. By examining the underlying
mechanisms that exacerbate T2D more effective treatments can be devised.
Cellular effects of insulin are mediated through binding with its canonical receptors,
namely inulin receptor (IR) and insulin growth factor-1 receptor (IGF-1R) (15). Specifically,
insulin binds to the insulin receptor's alpha subunit, which activates tyrosine kinase residues
within the beta subunit (16). Insulin receptor substrates (IRS) mediate intracellular signaling in
response to upstream activation of insulin receptors (17-19). Subsequent downstream events are
mediated by recruiting several adaptor molecules with unique motifs that guide specificity and
cellular outcomes (15-20). For example, cytoplasmic IRS-1 proteins contain multi 'docking'
sites with Src-homology-2 (SH2) and SH3 domains that mediate signal transduction (16).
Activation of phosphatidylinositol 3-kinase (PI3K)/Akt, ERK1/2, mTOR, and AMPK have
been associated with IRS-1 (17; 21; 22). Furthermore, IRS-1 has been implicated in several
pathologies, including type 2 diabetes and cancer (22).
Neuropilin 1 (Nrp1) was initially a coreceptor for class 3 semaphorins (Sema3), and
growth factors including vascular endothelial growth factor, transforming growth factor-β,
hepatocyte growth factor, and platelet-derived growth factor (8). Nrp1 is highly expressed in
vascular and myeloid cells (9; 10). This report proposes novel metabolic Neuropilin-1 (Nrp1)
functions as a major hub of well-coordinated and adaptive mechanism that supports tumor
growth and progression. Transmembrane Nrp1 receptor demonstrates pleiotropic cellular
functions, including independent and co-receptor interactions with endocrine growth factors,
such as VEGF, EGF, HGF, and Sema3 (11-14). Expectedly, Nrp1 functions may be responsive
to cellular microenvironments and the availability of secreted growth factors.
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With the ever-increasing prevalence of T2D and the associated metabolic perturbations
will heighten cancer incidence. Strong epidemiologic evidence also links T2D with increased
incidence of several types of cancer (1). Most importantly, aggressive growth and aberrant
cellular properties associated with malignant tumors benefit from metabolic and vascular
alterations. Insulin signaling proteins, mainly insulin receptor-A (INSRA) and Akt, often
demonstrate upregulated expression, as well as increased activation in tumor cells (2), (3).
Interestingly, abundant expression and phosphorylation of INSR have been observed in
mammary tumors from diabetic mice (4). While various animal and human studies and
epidemiological data recognize the association between obesity and cancer risk, molecular
mechanisms linking obesity, metabolic syndromes, and cancer remain incomplete.
In this study, we investigated potential links between insulin-related substrates and Nrp1
receptor protein in response to metabolic perturbations associated with obesity. Here, we report
novel metabolic roles of Nrp1 receptor with direct relevance to insulin signaling.

4.3

Results
4.3.1

Insulin Instigates Enhanced Nrp1 Expression and Vascular Function.

Vascular Nrp1 expression and functions have been well described in cancer biology (7;
12). To test the response of vascular Nrp1 to circulating insulin, HUVECs and VSMCs were
exposed to insulin. Increased Nrp1 expression was evident upon insulin stimulation, with
stronger levels observed in endothelial (HUVEC) relative to smooth muscle cells (VSMC) (Fig.
14A-C). Akt, a critical downstream substrate of the insulin signaling pathway, was activated in
response to insulin stimulation in HUVECs as well as VSMCs (Fig. 14A). Furthermore, Nrp1
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mRNA expression was elevated by insulin in a time and dose dependent manner in HUVEC
(Fig. 14D and E). HFD induced T2D results in increased Nrp1 expression in the endothelial
and smooth muscle layers (Fig. 14F). To test whether Nrp1 upregulation was specific to insulin,
HUVECs were exposed to different growth factors, including IGF-1, EGF, FGF2, HGF, VEGF,
and TGFβ1. Results indicated that Nrp1 expression was enhanced further by the presence of
several growth factors (Fig. 14G) and is consistent with earlier described pleiotropic Nrp1 coreceptor functions (24). However, downstream activation of Akt in response to growth factors
was negligible, except for HGF and insulin-treated cells (Fig. 14G). Insulin stimulation can
cause the activation of ENOS leading to vascular dilation however, Nrp1 silencing inhibitions
ENOS which can lead to decreased vasodilation.

F.

G.

Figure 14: Insulin enhances Nrp1 expression and vascular function
(A) HUVEC and HVSMCs were challenged with insulin (50 nM). Nrp1 and Akt protein
levels were assessed by Western blot. (B/C) Nrp1 staining (green) of HUVEC and SMC after

60
challenging with insulin. Actin filament (red). (D/E) HUVECs were challenged with insulin at
different time and doses and Nrp1 mRNA expression was assessed. (F) IF staining aorta of Chow
and HFD fed mice for Nrp1 Expression. (G) Immunoblot analysis of HUVECs challenged with
different growth factors.

4.3.2

In vivo Deletion of Nrp1 on Obesity-Induced Type II Diabetes

To understand the role that Nrp1 plays in the pathology of T2D in vivo, age-matched
mice littermates were placed on either a high-fat diet (HFD; ~60kCal) or a normal chow diet
(NCD) for 6 months. Body weights were routinely recorded, and blood glucose (GTT) levels
were measured following overnight fasting. HFD resulted in a marked increase in body weight
and blood glucose levels relative to chow fed mice (Fig. 15A-D) in both male and female mice.
The liver samples of high fat diet fed mice showed strongly upregulated Nrp1 expression (Fig.
2F). To understand the effect of Nrp1 deficiency and glucose tolerance in vivo Nrp1endo-/- mice
were utilized. These mice and their littermates were fed with chow or HFD for ~6months and
glucose and insulin tolerance tests (GTT and ITT) were carried out. The results showed that
endothelial specific Nrp1 deficiency improved the glucose tolerance (Fig. 15A-D). IHC staining
of Nrp1 in these mice demonstrate an increase in expression after HFD in WT mice compared
to Nrp1endo-/- mice. Together, these data suggest that vascular Nrp1 expression and functions are
modulated by insulin. Once we determined that Nrp1 deletion could provide a protective effect
on T2D mice needed to examine the how Nrp1 modulates insulin pathway activation. Nrp1 was
silenced in HUVECs and exposed to insulin a time and dose dependent manner. Nrp1 silencing
resulted in elevated Akt phosphorylation (Ser473) compared to control cells. It can be observed
that Akt phosphorylation exhibited prolonged activation compared to the sinusoidal
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phosphorylation in the control. Thus, demonstrating that Nrp1 can inhibit insulin pathway
activation. Finally, we examined the effect of Nrp1 expression in white adipose tissue (WAT),
a highly metabolic tissue. T2D resulted in accumulation of Nrp1 in the adipose tissue. As shown
via WB analysis of WAT (Fig 19A&B).

E.
CHOW

WT

HFD

NRP1-/-

Nrp-1

Aorta

F.

50nM INS
siControl

G.
siNRP1

0 5 15 30 60 120 0 5 15 30 60 120 mins

Nrp1
P-AKT S473
AKT
B-Actin

H.
siControl

J.

siNRP1

0 10 25 50 100 200 0 10 25 50 100 200 nM INS

Nrp1
P-AKT S473
AKT
B-Actin

Figure 15: In vivo, Analysis of Nrp1 Expression in Type II Diabetic Conditions
(A-D) Glucose tolerance test for Chow (CD) and high fat diet (HFD) for WT and
endo-/-

Nrp1

. (E) IHC of Nrp1 in aortas from WT and Nrp1

endo-/-

demonstrating Nrp1 is elevated in

HFD. (F) Immunoblot for Nrp1, p-AKT S473, AKT, and β-actin for insulin time dependent
exposure. (G) Relative p-AKT S473 levels for time dependent exposure. (H) Immunoblot for
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Nrp1, p-AKT S473, AKT, and β-actin for insulin dose dependent exposure. (I) Relative p-AKT
S473 levels for dose dependent exposure.

4.3.3

Nrp1 Colocalization and Effect on Insulin Pathway Activation in Endothelial
Cells

Potential interaction of Nrp1 with insulin-related substrates was explored beyond the
upregulated expression of Nrp1 in response to insulin. First, co-localization of Nrp1 with insulin
receptor β (IRβ), insulin-like growth factor 1b receptor (IGF1R), and IRS-1 was analyzed in
HUVEC cells. Relative to non-stimulated cells, Nrp1 upregulation and enhanced colocalization with IRβ was evident upon insulin stimulation (Fig. 16A). A similar trend was
confirmed between Nrp1 and IRS-1, and Nrp1 and IGF1R (Fig. 16B-C). These data indicate
increased interaction between Nrp1 and insulin-related targets in response to insulin
stimulation.
To further unravel the complex signaling interplay mediated by the availability of
several upstream insulin receptors, we focused on immediate IRS-1 downstream substrate of
the insulin receptors, given its well-established roles in cancer biology (22). Once we identified
the colocalization of Nrp1 and IRS1 the next step was to determine if there was direct
interaction. Also, insulin stimulation results in increased IRS1 phosphorylation at Ser612
recapitulating previously reported data. Pulldown of IRS1 was utilized to determine if there
was a direct interaction with Nrp1. In HUVECs, the interaction was confirmed following the
pull-down of IRS-1 under basal conditions and immunoblotting for Nrp1 (Fig. 16D). Thus,
lending evidence that Nrp1 has direct effects on the insulin signaling pathway. Further analysis
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of this interaction is necessary to understand the function. Given the abundance of Nrp1
expression in H1792 cancer cells, a similar pull-down of IRS-1 protein was performed in the
presence or absence of insulin stimulation. Immunoblot of Nrp1 again demonstrated close
interaction with IRS-1 in insulin-treated or untreated cells (Fig. 20A). However, reverse
immunoprecipitation of Nrp1 showed decreased interaction with IRS-1 within insulin-treated
cells (Fig. 20B). The data suggest decreased availability of IRS-1 protein following stimulation
with insulin. IRS-1 possess multiple phosphorylation sites that mediate the complex regulation
of specific downstream targets (28). In vascular cells, the IRS-1/PI3K/Akt pathway has been
linked with endothelial function via insulin-mediated synthesis of eNOS (28).

It was

determined that Nrp1 alters activation of eNOS in a time and dose dependent manner (Fig.
20C&D). Specifically, phosphorylation of IRS-1 at serine-612 has been implicated with
dissociation of p85 subunit of PI3K, resulting in further inhibition of signaling (28).
When it comes to insulin signaling, we need to first examine the effect loss of Nrp1 has
on activation of IR. Nrp1-silencing results in alterations activation of IR at activation sites
Y11146, and Y1150/1151 in a time dependent manner. Y1150/1151 phosphorylation was
prolonged after Nrp1 loss, and Y1146 activation was blunted (Fig. 16E). Nrp1 appears to alter
the phosphorylation and activity of IR. Dose dependent insulin stimulation also alters the
phosphorylation states of IR after Nrp1 loss (Fig. 16F). IR phosphorylation directly activates
downstream receptors that propagate insulin signals such as IRS1. We, therefore, further
analyzed phospho-IRS1 (Ser612 & Ser636/639) in Nrp1-expressing or deficient HUVECs
following time-dependent insulin stimulation. As shown above of Nrp1, insulin stimulation
enhanced further the expression of Nrp1 but attenuated phosphorylation of IRS-1 (Fig. 15E and
Fig. 16E). In Nrp1-depleted cells, phospho-IRS-1 was decreased but demonstrated stronger
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activation of Akt in response to insulin (Fig. 14F&H). Finally, dose-dependent insulin
stimulation elicited a similar enhanced IRS-1 and Akt activation pattern in Nrp1-deficient cells
relative to Nrp1-expressing cells (Figure 14H & 16F). Upregulated Nrp1 expression in response
to dose-dependent insulin stimulation correlated with diminished phospho- IRS-1 and elevated
Akt (Fig. 16F). These data suggest that Nrp1 attenuates the canonical insulin signaling pathway
and uncovers novel connections between Nrp1 and insulin signaling.
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Figure 16: Nrp1 modulates insulin signaling pathway
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(A) IF costaining of HUVECs for Nrp1 (Green) and IRβ (red) (B) IF costaining of
HUVECs for Nrp1 (Green) and IGF1Rβ (red). (C) IF costaining of HUVECs for Nrp1 (Green)
and IRS1 (red). (D) At basal condition the HUVEC cells homogenates were used to pull down
the pIRS1 (Ser612) and Nrp1 binding was demonstrated. (E) Examination of insulin signaling
pathway perturbations in a time dependent manner. (F) Examination of insulin signaling pathway
perturbations in a dose dependent manner

4.3.4

Nrp1 Attenuates the Availability and Distribution of Intracellular Insulin.

To gain further insights into novel associations between Nrp1 and insulin family
members, FITC-labelled insulin was employed either alone or following 15 minutes pretreatment of serum-starved HUVEC cells with unlabeled insulin. As expected, non-treated and
unlabeled cells displayed negligible signal detection by flow cytometry (Fig. 17A&B).
However, FITC-insulin treatments displayed attenuated signal detection in Nrp1-expressing
HUVECs relative to Nrp1-deficient cells (Fig. 17A&B). Conversely, when cells were pretreated
with unlabeled insulin before FITC-insulin stimulation, signal detection in the presence or
absence of Nrp1 was attenuated (Fig. 17A&B). The data suggest that pretreatment with
unlabeled insulin promotes internalization of cell surface insulin receptors, resulting in depleted
insulin receptor and availability for binding upon subsequent stimulation with FITC-labeled
insulin. Subsequent gain-of-function experiments employed transfection of Nrp1-expressing
plasmid in H1299 cells. Interestingly, a similar trend of attenuated FITC-insulin signals was
detected in Nrp1-expressing cells relative to empty-vector controls (Fig. 16C&D).
Immunofluorescence microscopy further revealed a distinct perinuclear distribution of FITCinsulin in Nrp1-deficient cells; however, the distribution pattern was disrupted by the presence
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of Nrp1 expression (Fig. 16E). Taken together, dispersed insulin distribution and attenuated
availability in the presence of Nrp1 support the modulation of insulin signaling by Nrp1.

A.

B.

C.

D.

E.

Figure 17: Nrp1 attenuates availability and distribution of intracellular insulin
(A,B). FACS analysis and measurement of insulin internalization after siRNA mediated
depletion of Nrp1 in HUVEC cells. (C,D) FACS analysis and measurement of insulin
internalization after Nrp1 overexpression in Nrp1-deficient H1299 cells. (E) H1299 cells were
transfected with Nrp1 overexpressing plasmid and stimulated with insulin. FITC-conjugated
insulin was further used to observe the localization of Nrp1. Nucleus (DAPI, blue), Insulin-FITC
(green) and Nrp1 (red).
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4.3.5

Insulin Promotes Nrp1 Upregulation in Cancer Cells

Based on established links between Nrp1, cancer, and vascular tissue (25-27), we
analyzed the response of Nrp1 to insulin stimulation across multiple cancer cells. First,
heightened Nrp1 protein expression was confirmed in H1792 lung cancer cells relative to
metabolically relevant adipose cells (Fig. 18A). Next, we validated basal Nrp1 expression in
multiple cancer cell lines and MRC9 cells (non-cancer lung cells). With exception of H1299
cells, varying Nrp1 protein levels were detected across several other cell lines including MRC9,
A549, H1792 and H1650 (Fig. 18B). Subsequently, transient Nrp1 deletion was performed in
HepG2, A549, H1650, and H1972 cells and exposed to insulin (Fig. 18C&D). The results
consistently demonstrated insulin-specific upregulation of Nrp1 expression (Fig. 18C&D).
Surprisingly, Akt activation in response to insulin was blunted in Nrp1-expressing HepG2 cells,
suggesting that Nrp1 may interfere with insulin-mediated signaling (Fig. 18C). Gain-offunction analysis involved exogenous Nrp1 expression in H1299-deficient cells; however, Nrp1
levels were comparable in the presence or absence of insulin (Fig. 18D). At the mRNA level,
rapid Nrp1 upregulation was evident by insulin stimulation in HepG2, H1792, H1650 and A549
cells (Fig. 18E&F). Conversely, negligible Nrp1 mRNA expression was observed following
insulin stimulation of LacZ-transfected H1299 cells but peaked at 60 minutes upon exogenous
Nrp1 transfection (Fig. 15H). Together, these data strongly suggest modulation of Nrp1
expression by insulin.
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Figure 18: Insulin promotes Nrp1 upregulation in multiple cells
(A) Immunoblot analysis of Nrp1 expression in pre and post adipocytes, with control
H1792 lung cancer cells. (B) Immunoblot analysis of Nrp1 expression across multiple cancer cell
lines (A459, H1299, H1792 and H1650). H1299 is Nrp1-deficient, and MRC9 is non-cancer lung
cell line. (C/D) HepG2, A549, H1650 and H1792 cells were transfected with siNrp1 to silence
the Nrp1 expression and challenged with insulin. Nrp1 and GAPDH expressions were assessed
by Western blot. Exogenous Nrp1 expression was undertaken in H1299-deficient cells. (E-G)
Nrp1 mRNA in response to insulin stimulation across multiple cancer cell lines. (H) Insulin
stimulation following exogenous Nrp1 expression in H1299-deficient cells.
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4.4

Supplementary Figures

A.

B.

Supplementary Figure 7: (A&B)High Fate Diet results in accumulation of Nrp1 in WAT.

Figure 19: High Fat Diet Effect on Nrp1 Expression
(A&B) High Fate Diet results in accumulation of Nrp1 in WAT.
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Supplementary Figure 8: (A) H1792 cells challenged with insulin (50nM; 15min) and IRS1 was pulled down and Nrp1 binding was
confirmed (B) H1792 cells challenged with insulin (50nM; 15min) and reverse pull down was done for Nrp1 and IRS1 binding was
Figure 20: Nrp1 Interaction with IRS1
confirmed. (C) Time dependent analysis of p-ENOS S1177. (D) Dose dependent analysis of p-ENOS S1177 due to Nrp1 silencing.

(A) H1792 cells challenged with insulin (50nM; 15min) and IRS1 was pulled down and
Nrp1 binding was confirmed (B) H1792 cells challenged with insulin (50nM; 15min) and reverse
pull down was done for Nrp1 and IRS1 binding was confirmed. (C) Time dependent analysis of
p-ENOS S1177. (D) Dose dependent analysis of p-ENOS S1177 due to Nrp1 silencing.
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5.1

DISCUSSION AND CONCLUSION

Indoxyl Sulfate Effect on Vascular Repair
Vascular complications are a known hallmark of CKD progression (1). This study

demonstrated that uremic toxin IS directly inhibited vascular regeneration and arteriogenesis
through alterations to the actin cytoskeleton, disruptions to actin polymerization, loss of focal
adhesions, and cellular attachment. IS-exposure drastically altered the expression of canonical
focal adhesion proteins FAK, and Paxillin in both in vitro and in vivo models. These major
components of focal adhesions are necessary for proper formation and structure. Loss of focal
adhesions, due to uremic toxin accumulation, will interfere in response to extracellular stimuli
necessary for vascular regeneration. Impaired vascular regeneration due to the loss focal adhesions
would account for data from CKD mice which exhibited defective blood flow restoration.
Understanding how focal adhesion are involved in vascular regeneration during CKD progression
is necessary.
Vascular regeneration and arteriogenesis are necessary processes responsible for blood
vessel expansion and repair of damaged vessels. Vascular damage would lead to multiple
complications including but not limited to ischemia, necrosis, amputations, infections, and
ultimately patient mortality (2). Blood vessel expansion is achieved through the recruitment of
VSMCs, which provide structural support. Without this support vessels would experience blood
leakage into tissues and decreased extremity flow. Recovery of CKD patients would experience
increased recovery time or in extreme cases infection, amputation, and death (2-3). Examination
of the role CKD and the resultant accumulation of uremic toxins has on vascular regeneration is
necessary
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Particular attention was paid to FAK which plays roles in cytoskeleton formation,
activation, cellular motility, and potentiation of extracellular signals. IS-induced loss of FAK
directly contributed to lost motility in VSMCs. VSMCs that are defective in migratory ability
would significantly contribute to impaired vascular regeneration and arteriogenesis. Thus, our
data lent compelling evidence that CKD-induced loss of FAK has a direct effect over vascular
regeneration. Understanding that loss of FAK plays a significant role in impaired motility the next
step was to examine downstream effectors interact with actin. Examination demonstrated that NWASP was significantly decreased by CKD progression and IS-expsoure. Wiskott-Aldrich
Syndrome (WAS) a known genetic condition that is characterized defective actin fiber formation.
N-WASP is a member of the (WAS) family of proteins and deficiency can lead to similar
abrogation’s of the actin cytoskeleton. However, abrogation of the actin cytoskeleton does not
rest with N-WASP alone. N-WASP activates the Arp2/3 complex, a well described actin regulation
complex. Alterations to Arp2/3 activation or expression as, demonstrated in our analysis, would
directly inhibit actin fiber formation (4-5). Knowing, that IS-exposure and CKD progression
negative impact activation of actin polymerization, our observations of inhibited actin
polymerization and altered morphology are understandable. Without input from control pathways
actin would be unable to respond to impaired stimulation and will exacerbate vascular
complications. Taken together, our data demonstrated that CKD progression has a negative impact
on focal adhesion formation all the way cytoskeletal control. If these pathways are inhibited, then
VSMCs would be able to participate in vascular regeneration and arteriogenesis necessary for
blood flow restoration and prevention of ischemic tissue injury.
Demonstration of the adverse effects CKD progression and IS accumulation has on
vascular regeneration provides insights into previous clinical reports of vascular damage. CKD
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patients who were afflicted by multiple vascular complications that can be related to impaired
vascular regeneration. Firstly, CKD patients presenting with AAAs, and have undergone surgical
repair, are increased mortality risk due to repair failure.

Secondly, vascular canula for

hemodialysis of CKD patients are vulnerable to vessel leakage (6). Finally, CKD/diabetic patients
who undergo extremity amputation decreased would healing and elevated rates of mortality (7).
Our data could provide insights into the molecular basis for these phenomena, from the loss of
FAK to impaired actin polymerization, and provide a window into possible mitigation strategies
or treatments.
By demonstrating that uremic toxins directly impact vascular health and repair capacity it
becomes necessary to postulate future mitigation strategies. We in this study detail an outcome
that has been observed partially in clinical settings but has not been examined on a mechanistic,
or phenotypic level. Renal specialists have noticed numerous complications that arise from
vascular injuries but have not completely confirmed a link between CKD and defective repair
mechanisms. By understanding how this process occurs due to IS accumulation we can then better
direct treatments and possibly decrease the mortality rate in CKD patients further. These can be
achieved through employing new dialysis methods to remove uremic toxins or direct inhibition of
IS production by the liver by targeting sulfotransferase Sult1A1 (8-10). Inhibition of this enzyme
will decrease the levels of circulation IS and mitigate the damage that could occur.

By

understanding the role IS plays in vascular injury it is hoped that this data will open new
therapeutic avenues to treat or in certain cases prevent the injury all together.

Along with

inhibiting the formation of IS by sulfotransferases it is possible to prevent precursor formation via
tryptophan restricted diet. However, tryptophan depletion as a treatment model is controversial.
Data has demonstrated both beneficial and adverse complications that arise from dietary restriction
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(11-12). Tryptophan as an essential amino acid is necessary for the productions of multiple
biologically relevant metabolites. Insufficient level of tryptophan lead to alterations in metabolite
production and can have adverse effects on mental health and sleep. Understanding how to
regulate the role and function of tryptophan and its metabolites is essential for effective treatment.
More work is necessary to elucidate the roles each metabolite has in CKD pathology.
When examining arteriogenesis for this study there were a few limitations for this study.
Currently there are short coming in fully examining arteriogenesis due to the simple reason no
sufficient model has been found to allow direct examination of the process. In vitro models are
insufficient in replicating arteriole formation due to lacking a viable matrix to induce formation.
Arteriole formation is a complex process that involves first capillary formation through single
layer endothelial cells followed by expansion support from VSMCs. However, there are many
questions that remaining concerning the exact formation and environmental components necessary
to achieve vessel expansion and blow flow capacity. We are also limited in understanding CKD
mitigation strategies including, hemodialysis and oral sorbents to remove uremic toxins from the
intestinal tract, will influence observations in this study.
In summary, our study has provided compelling evidence that uremic toxins, in vitro and
in vivo, have deleterious effects on vascular regeneration and arteriogenesis. By elucidating the
molecular mechanisms altered by IS-exposure, our study provides novel insights into CKD
progression and opening new avenues for treatment strategies.

5.2

Nrp1 Effect on Vascular Endothelial cell Response to Insulin Signaling
In this study, we demonstrate that obesity induced T2D, or elevated insulin secretion

promotes the expression of oncogene Nrp1 in vascular, adipose, and liver tissues, as well as
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vascular and cancer cells. The resulting increase of Nrp1 availability promotes further
interaction with insulin receptors and substrates, thereby modulating insulin signaling functions
in cancer and metabolically active tissues. As observed in our findings, Nrp1 responds to
insulin exposure in vascular and epithelial cancer cells. Therefore, increased Nrp1 expression
under obese conditions can alter the activity and responsiveness of insulin receptors. In a
process reminiscent to a negative feedback mechanism, Nrp1 acts as a roughe receptor protein
that interferes with insulin substrates, culminating in the modulation of insulin signaling
functions. This sequence of events supports metabolic dysregulation, such as insulin resistance
and oncogenic signaling and proliferation of cancer cells. Collectively, our data for the first
time uncover novel Nrp1 functions at the nexus of obesity, insulin resistance and cancer
metabolism with profound implications for diagnostics and therapeutics.
Across multiple cell types, including vascular (HUVEC and VSMC) and cancer cells,
insulin stimulation resulted in rapid upregulation of Nrp1 at the mRNA and protein levels. Colocalization of Nrp1 with insulin substrates, namely IGF1Rβ, IRβ and IRS-1 enhanced
aggressive Nrp1 colocalization. Novel links between Nrp1 and insulin family members are
highly significant, directly relevant to several pathological conditions. Further analysis of
insulin receptors demonstrates that Nrp1 has a direct effect on activation and propagation of
signals. As alterations to the insulin signaling occur due to Nrp1 loss this can open new avenues
for understanding its role in T2D. Recent global events have demonstrated the importance of
understanding the broad functions that Nrp1 is involved. Nrp1 acting as a coreceptor to ACE2
for Sars-CoV-2 infectivity there is new urgency to delineate the metabolic implications these
interactions are involved in. Based on our findings it is necessary to examine the effects that
newly discovered Nrp1 pharmacological inhibitors that have been utilized to impeded Sars-

82
CoV-2 infections. If these inhibitors can ameliorate the symptoms of T2D then we will have
opened new avenues to treat this ever-increasing disease condition.
The high fat diet fed, endothelial specific Nrp1 deficient mice showed improved glucose
tolerance. This finding significantly impacts current knowledge relevant to disease etiology,
diagnosis, and treatments of metabolic disorders associated with T2D. For example, vascular
and metastatic alterations that promote tumor angiogenesis depend on the utilization of cellular
nutrients that support the rapid development and spread of vessel networks (13-14). Beyond
maintenance of glucose and lipid homeostasis, insulin promotes vasodilatation via PI3K/Akt
mediated activation of endothelial nitric oxide (NO) synthase (eNOS) (15). Loss of Nrp1
decrease activation of eNOS within endothelial cells. If this blockage occurs, due to the loss of
Nrp1, vasodilation will not occur preventing nutrient flow to cancer cells, or augment tumor
microenvironments and metastasis. Independently, Nrp1 and insulin substrates have been
implicated in multiple cellular pathways, including mTOR, which plays established roles in
autophagy and cancer (16-17). As Nrp1 is an oncogene and obesity/diabetes are known to have
elevated risks of cancers, it is plausible that insulin (growth factors) induces Nrp1 expression
resulting in insulin resistance and elevated risk of cancers.
For the first time, these findings implicate Nrp1 as a novel insulin receptor and expand
further the repertoire of growth factors that interact with Nrp1 to mediate cellular events.
However, additional studies are required to fully understand confounding observations. Wilson
et al, reported that Nrp1 expression in adipose tissue macrophages (ATMs) protect against
obesity and metabolic syndromes (18) and is consistent with our study in myeloid-specific Nrp1
deficient mice (19). Secreted factors influenced by obesity include circulating free fatty acids
(20). However, cellular responses by ATMs may be context dependent. Given the lethality of
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global Nrp1 deletion, tissue-specific Nrp1 ablation in macrophages, endothelial and adipose
cells (in vivo and in vitro) will be necessary to decipher cell-specific Nrp1 functions completely.
Furthermore, specific Nrp1 protein domain(s) critical for interaction with insulin
substrates, as well as modulation of insulin signaling requires elucidation. Potential codomain
cooperativity between SH3-PDZ domains of Nrp1 and effector binding sites of insulin-related
substrates, such as IRS-1, will be investigated. To this end, we have generated Nrp1 constructs
that lack cytoplasmic and/or extracellular domains to clarify specific regions involved with
insulin substrates. Additionally, the contributions of various phosphatases that inhibit aberrant
insulin phosphorylation remain unknown (21). Findings from this study raise thoughtprovoking questions related to the expression and function of Nrp1 in obese or insulin-resistant
cancer patients. As growth factors such as HGF and insulin can activate PI-3 kinase and PI3
kinase is known to promote cancers, increased Nrp1 expression in insulin/HGF-stimulated cells
might be PI-3 kinase-dependent. Thus, clarifying the contribution of PI-3 kinase in growth
factors-induced Nrp1 is essential.
Elucidation of the role Nrp1 plays in insulin signaling will open new avenues of
treatment. Recent developments in Nrp1 inhibitors could provide effective treatments to
improve T2D progression.
5.3

CONCLUSION
Prevalence of chronic kidney disease has been steadily increasing over the last couple of

decades to where it affects approximately 1 in 7 Americans. Examination and understanding of
underlying conditions and subsequent complications will provide valuable knowledge during
treatment. Firstly, we demonstrate that accumulation of uremic toxin IS results in defective
vascular repair potential. Disruption of focal adhesion related proteins, namely FAK, leads to
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decreased actin polymerization and decreased wound repair. Patients have been observed
exhibiting adverse outcomes after various vascular injuries from lower extremity amputations to
AAA repairs. Understanding the deleterious effects of uremic toxin accumulation on CKD
patients allows for targets treatment strategies. Along with examining the effects of CKD it is
important to examine comorbidities, including Type II Diabetes, associated with disease
progression.
Type II Diabetes a condition known to be exacerbate CKD progression was examined.
T2D prevalence has exploded over the last couple of decades. We demonstrate that as T2D
progresses there is a significant increase in oncogenic protein Nrp1. Increased expression of Nrp1
leads to alterations in the insulin signaling pathway and exacerbation of T2D. However, we
demonstrated that loss of Nrp1 could help protect against T2D and lessen the symptoms. Recently,
there have been multiple Nrp1 inhibitors developed to help combat Sars-CoV-2 infections.
Examination of the effectiveness of these inhibitors could open new strategies to treat T2D and
help prevent CKD progression.
5.4
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